Scientific Advisory Board
Clinical Advisory Board

Scientific Advisory Board

Adrian L. Harris, MB, ChB, Ph.D.

Dr. Harris is Cancer Research UK Professor of Clinical Oncology at the University of Oxford, and Director of the Cancer Research UK Molecular Oncology Laboratories at the University's Weatherall Institute of Molecular Medicine. He is involved in clinical trials of anti-angiogenesis therapy, signal blockade inhibitors and immunotherapy. His clinical research interests include breast cancer, melanoma, and renal cancer.

Dr. Harris trained in Liverpool Medical School, the John Radcliffe Hospital, the Royal Free Hospital and the Royal Marsden Hospital. He is Head of the Medical Oncology Research Team that provides research-based treatments integrated with National Health Service care at the Cancer Research UK Medical Oncology Unit on the Churchill Hospital site.

He has published many papers and is on the editorial boards of several leading cancer journals including Cancer Cell and Clinical Cancer Research. His laboratory interests include angiogenesis and the role of hypoxia in tumor biology and as targets for therapy.

Robert S. Kerbel, Ph.D.

Dr. Kerbel is known internationally for his research into cancer metastasis, drug resistance and tumor angiogenesis. He is a Senior Scientist, as well as the Canada Research Chair in Molecular Medicine at Sunnybrook and Women's College Health Sciences Centre in Toronto and Professor of the Department of Medical Biophysics at the University of Toronto. He is the author of more than 270 scientific papers and the recipient of numerous scientific awards. Dr. Kerbel serves on the editorial boards of many scientific journals, including Cancer Research, Clinical Cancer Research, Molecular Cancer Research and Angiogenesis. He was Editor-in-Chief of Cancer & Metastasis Reviews from 1991-2001. He currently serves as a member of OXiGENE's Scientific Advisory Board. Dr. Kerbel received his B.S. from the University of Toronto and his Ph.D. in immunology from Queen's University. He was a post-doctoral fellow in cancer biology at the Chester Beatty Research Institute in London, England.

Dietmar W. Siemann, Ph.D.

Dr. Siemann is a leading radiotherapy, anti-angiogenesis and vascular targeting researcher. He is the John P. Cofrin Professor for Research in Radiation Oncology at the University of Florida College of Medicine in Gainesville. In addition, he is a professor in the school's Department of Pharmacology and Therapeutics. Dr. Siemann has authored more than 150 scientific papers and is the recipient of numerous scientific awards, including the Research Award of the Radiation Research Society in Oak Brook, Illinois (1990). He is the former Chairman of the National Cancer Institute's Radiation Study Section (1996-1998). At the University of Florida College of Medicine, Dr. Siemann's research focuses on the effects of the tumor microenvironment on patient outcome. Dr. Siemann received his BS in Physics from the University of Manitoba and his Ph.D. in Medical Biophysics from the University of Toronto. He completed post-doctoral work in radiobiology at the University of Rochester (NY).

Clinical Advisory Board

A. Hilary Calvert, MB, BChir, M.D.

Dr. Calvert is the Clinical Director of the Northern Institute for Cancer Research and Professor of Medical Oncology at the University of Newcastle upon Tyne, England. His training is in Medicine, Mathematics and Biochemistry. He has had a long involvement in anticancer drug development starting while he was working at the Institute for Cancer Research / Royal Marsden Hospital in London. Since 1989, he has worked in the University of Newcastle at Tyne and has implemented a program of drug development, aimed at using the molecular pathology of human cancers to define targets, developing drugs aimed at those targets and performing preclinical and early clinical studies. In 2005 he was awarded the Pfizer Research Innovation Award for his work on developing new anticancer drugs.

Jeffrey S. Heier, M.D.

Dr. Heier is a Vitreoretinal Specialist at Ophthalmic Consultants of Boston, Co-Director of the Vitreoretinal Fellowship at OCB/Tufts Medical School, and President of the Center for Eye Research and Education in Boston, Massachusetts. Dr. Heier’s academic appointments include an instructorship in ophthalmology at Tufts University School of Medicine and Harvard University Medical School, both in Boston. Dr. Heier received a medical degree from Boston University School of Medicine in Massachusetts, and subsequently completed a transitional internship, ophthalmic residency, and vitreoretinal fellowship at Fitzsimons Army Medical Center. Additional postgraduate training includes a vitreoretinal fellowship completed at Ophthalmic Consultants of Boston/Tufts University School of Medicine. Dr. Heier’s research interests are focused on age-related macular degeneration (ARMD), diabetic retinopathy, and innovation in vitreoretinal surgical instrumentation: areas he has pursued as lead or principal investigator in numerous clinical trials.

Stanley B. Kaye, M.D.

Dr. Kaye is currently Head of the Drug Development Unit and Head of the Section of Medicine at the Royal Marsden Hospital/Institute of Cancer Research, London. He previously was Head of the Gynaecology Unit at the Royal Marsden Hospital. He is now responsible for overseeing and managing one of the world’s largest Phase I clinical trial units. He is the author of over 300 peer reviewed papers, he sits on the Editorial Board of 12 cancer journals, and has held various national and international responsibilities, most notably in Cancer Research UK for which he currently chairs the Clinical and Translational Research Committee.

Hakan Mellstedt, M.D., Ph.D.

Dr. Mellstedt is Professor of Oncologic Biotherapy at the Karolinska Institute and Administrative Director of Cancer Center Karolinska, Karolinska Institute, Stockholm, Sweden. He holds a position as Chief Physician at the Department of Oncology (Radiumhemmet), Karolinska Hospital, Stockholm and has specialist certificates in Oncology, Hematology and Internal Medicine. He is the Chairman of the Swedish Society of Oncology. Professor Mellstedt is currently a member of the Editorial Board of several international scientific journals and has published more than 375 articles in the areas of hematology, medical oncology, tumor immunology and the development of immunotherapeutics/biotherapeutics in hematological malignancies as well as in solid tumors. Professor Mellstedt is the Chairman of OXiGENE's Clinical Trial Advisory Board.

Lee S. Rosen, M.D.

Dr. Rosen is the Director of Developmental Therapeutics for the Cancer Institute Medical Group, affiliated with the John Wayne Cancer Institute in Santa Monica. He is the former Adjunct Assistant Professor at UCLA's Department of Medicine, Division of Hematology-Oncology, and served as Director of UCLA's Cancer Therapy Development Program from 1996-2002. Dr. Rosen serves as the principal investigator for many Phase I and II clinical trials, focusing on novel agents in general, and angiogenesis inhibitors in particular.

Gordon J.S. Rustin, M.D.

Dr. Rustin is the Director of Medical Oncology at Mount Vernon Hospital, which is the largest cancer center in the South of England. He has published widely on management of gynecological cancers and germ cell tumors and the use of tumor markers. He has developed response criteria on CA125, which are now increasingly used in Phase II trials of ovarian cancer. He has recently been the principal investigator of two trials of vascular targeting agents, as well as several trials in ovarian cancer. He was awarded an Honorary Professorship by University College London in March 2001.

Jan B. Vermorken, M.D., Ph.D.

Dr. Vermorken is Professor of Oncology and head of the Department of Medical Oncology of the University Hospital of the University of Antwerp, Belgium. Professor Vermorken has held numerous functions with the Dutch Cancer Society and the European Organization for Research on Treatment of Cancer (EORTC), and currently is a member of EORTC's Early Clinical Studies Group and the Subcommittee for Chemotherapy of EORTC's Head and Neck Cancer Cooperative Group. Professor Vermorken has lectured extensively in the area of gynecological oncology and currently serves of the Editorial Board of the International Journal of Gynecological Oncology.